Treatment patterns and associated costs with Parkinson's disease levodopa induced dyskinesia

Journal of the Neurological Sciences

Volumn 319, Issue 1-2, 2012, Pages 24-31

  Suh, Dong Churl ^a   Pahwa, Rajesh ^b   Mallya, Usha ^c  

^a Chung Ang University   (South Korea)

^b UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Dyskinesia; Levodopa; Parkinson's disease; Treatment costs; Treatment patterns

Indexed keywords

AMANTADINE; CATECHOL METHYLTRANSFERASE INHIBITOR; CHOLINERGIC RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; MONOAMINE OXIDASE B INHIBITOR;

ADULT; AGED; ARTICLE; BRAIN DEPTH STIMULATION; BRAIN SURGERY; COMORBIDITY; CONTROLLED STUDY; DRUG COST; DRUG INDUCED DISEASE; DRUG WITHDRAWAL; FEMALE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HUMAN; LEVODOPA INDUCED DYSKINESIA; MAJOR CLINICAL STUDY; MALE; PARKINSON DISEASE; PATIENT COMPLIANCE; PRIORITY JOURNAL; PRIVATE HEALTH INSURANCE; PROPENSITY SCORE; RETROSPECTIVE STUDY;

ADULT; AGED; AGED, 80 AND OVER; ANTIPARKINSON AGENTS; DATABASES, FACTUAL; DYSKINESIA, DRUG-INDUCED; FEMALE; HEALTH CARE COSTS; HUMANS; INSURANCE, HEALTH; LEVODOPA; MALE; MIDDLE AGED; PARKINSON DISEASE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; UNITED STATES;

EID: 84862761427     PISSN: 0022510X     EISSN: 18785883     Source Type: Journal    
DOI: 10.1016/j.jns.2012.05.029     Document Type: Article

References (51)

1. Dorsey E, Constantinescu R, Thompson J. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology 2007;68:384-6. (Pubitemid 46184217)
2. Huse D, Schulman K, Orsini L. Burden of illness in Parkinson disease. Mov Disord 2005;20:1449-54.
3. Dodel RC, Singer M, Kohne-Volland R, Szucs T, Rathay B, Scholz E, et al. The economic impact of Parkinson's disease: an estimation based on a 3 month prospective analysis. Pharmacoeconomics 1998;14:299-312. (Pubitemid 28416933)
4. Ahlskog JE, Muenter MD. Frequency of levodopa-related dyskinesisa and motor fluctuations as estimated from the cumulative literature. Mov Disord 2001;16: 448-58. (Pubitemid 36041148)
5. National Institute for Health and Clinical Excellence. Parkinson's disease: diagnosis and management in primary and secondary care (NICE clinical guideline 35). London, UK: National Health Service; 2006.
6. Dodel RC, Berger K, Oertel WH. Health-related quality of life and healthcare utilisation in patients with Parkinson's disease: impact of motor fluctuations and dyskinesias. Pharmacoeconomics 2001;19:1013-38. (Pubitemid 33701931)
7. Chapuis S, Ouchchane L, Metz O, Gerbaud L, Durif F. Impact of the motor complications of Parkinson's disease on the quality of life. Mov Disord 2005;20:224-30. (Pubitemid 40361128)
8. Maurel F, Lilliu H, Le Pen C. Social and economic cost of L-Dopa-induced dyskinesias in patients with Parkinson's disease. Rev Neurol (Paris) 2001;157:507-14.
9. Fahn S. Medical treatment of Parkinson's disease. J Neurol 1998;245:P15-24.
10. Gottwald MD, Aminoff MJ. Therapies for dopaminergic-induced dyskinesias in Parkinson disease. Ann Neurol 2011;69:919-27.
11. Lang A, Houeto J, Krack P. Deep brain stimulation: preoperative issues. Mov Disord 2006;21:S171-96. (Pubitemid 44028281)
12. Pahwa R, Factor SA, Lyons KE, Ondo WG. Practice parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2006;66:983-95. (Pubitemid 44044780)
13. Pechevis M, Clarke CE, Vieregge P, Khoshnood B. Effects of dyskinesias in Parkinson's disease on quality of life and health-related costs: a prospective European study. Eur J Neurol 2005;12:956-63. (Pubitemid 41820050)
14. Findley L, Aujla M, Bain PG, Baker M, Beech C, Bowman C, et al. Direct economic impact of Parkinson's disease: a research survey in the United Kingdom. Mov Disord 2003;18:1139-45. (Pubitemid 37336937)
15. Whetten-Goldstein K, Sloan F, Kulas E, Custon T, Schenkman M. The burden of Parkinson's disease on society, family, and the individual. J Am Geriatr Soc 1997;45:844-9. (Pubitemid 27289932)
16. O'Brien JA, Ward A, Michels SL, Tzivelekis S, Brandt NJ. Economic burden associated with Parkinson disease. Drug Benefit Trends 2009;21:179-90.
17. Dodel R, Reese J-P, Balzer M, Oertel WH. The economic burden of Parkinson's disease. Eur Neuro Rev 2008;3:11-4.
18. Adamson DM, Chang S, Hansen LG. Health research data for the real world: The MarketScan Databases (white paper); 2008.
19. Ciranni MA, Kearney TE, Olson KR. Comparing acute toxicity of first- and second-generation antipsychotic drugs: a 10-year, retrospective cohort study. J Clin Psychiatry 2009;70:122-9.
20. Kenney C, Hunter C, Davidson A, Jankovic J. Metoclopramide, an increasingly recognized cause of tardive dyskinesia. J Clin Pharmacol 2008;48:379-84. (Pubitemid 351257774)
21. Parkinson Study Group. Entacapone improves motor fluctuations in levodopa-treated Parkinson's disease patients. Parkinson Study Group. Ann Neurol 1997;42:747-55.
22. Woerner MG, Alvir JM, Saltz BL, Lieberman JA, Kane JM. Prospective study of tardive dyskinesia in the elderly: rates and risk factors. Am J Psychiatry 1998;155:1521-8. (Pubitemid 28512019)
23. Clinical Policy Bulletin (Deep Brain Stimulation). Accessed Oct 08, 2011, at http://www.aetna.com/cpb/medical/data/200-299/0208.html 2011.
24. Clinical Policy Bulletin (Thalamotomy). Accessed Oct 14, 2011, at http://www.aetna.com/cpb/medical/data/100-199/0153.html 2011.
25. Stereotactic radiofrequency pallidotomy. Medical policy. Accessed Oct 10, 2011, athttp://www.anthem.com/medicalpolicies/policies/mp-pw-a050200.htm 2011.
26. Medical Policy (Deep Brain Stimulation). Accessed Oct 8, 2011, at http://www.empireblue.com/provider/noapplication/f2/s5/t9/pw-ad084959.pdf2011.
27. Deep Brain Stimulation. Accessed Oct 8, 2011, at https://www. unitedhealthcareonline. com/ccmcontent/ProviderII/UHC/en-US/Assets/ ProviderStaticFiles/ProviderStaticFiles Pdf/Tools%20and%20Resources/ Policies%20and%20Protocols/Medical%20Policies/ Medical%20Policies/Deep-Brain- Stimulation%20.pdf 2011.
28. Blanford L, Dans PE, Ober JD,Wheelock C. Analyzing variations inmedication compliance related to individual drug, drug class, and prescribing physician. J Manag Care Pharm 1999;5:47-51.
29. Sikka R, Xia F, Aubert RE. Estimating medication persistency using administrative claims data. Am J Manag Care 2005;11:449-57. (Pubitemid 41022729)
30. Sokol MC, McGuigan KA, Verbrugge RR, Epstein RS. Impact of medication adherence on hospitalization risk and healthcare cost. Med Care 2005;43:521-30. (Pubitemid 40847288)
31. Gu XS, Rosenbaum PR. Comparison of multivariate matching methods: structures, distances, and algorithms. J Comput Graphical Stat 1993;2:405-20.
32. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373-83. (Pubitemid 17055592)
33. Hosmer DW, Lemeshow S. Applied logistic regression. 2nd ed. New York, NY: John Wiley & Sons; 2000.
34. Agresti A. Categorical data analysis. 2nd ed. New York, NY: JohnWiley & Sons; 2002.
35. Desgagne A, Castilloux A-M, Angers J-F, LeLorier J. The use of the bootstrap statistical method for the pharmacoeconomic cost analysis of skewed data. Pharmacoeconomics 1998;13:487-97.
36. Kumar N, Van Gerpen JA, Bower JH. Levodopa-dyskinesia Incidence by age of Parkinson's disease onset. Mov Disord 2005;20:342-66.
37. Schrag A, Schott JM. Epidemiological, clinical, and gentic characteristics of early-onset parkinsonism. Lancet Neurol 2006;5:355-63.
38. Fahn S, Oakes D, Shoulson I, Kieburtz K, Rudolph A, Lang A, et al. Levodopa and the progression of Parkinson's disease. N Engl J Med 2004;351:2498-508.
39. Hauser RA, McDermott MP, Messing S. Factors associated with the development of motor fluctuations and dyskinesias in Parkinson disease. Arch Neurol 2006;63:1756-60. (Pubitemid 44925085)
40. Metman LV, Konitsiotis S, Chase TN. Pathophysiology of motor response complications in parkinson's disease: hypotheses on the why, where, and what. Mov Disord 2000;15:3-8. (Pubitemid 30037981)
41. Stacy M, Galbreath A. Optimizing long-term therapy for Parkinson disease: options for treatment-associated dyskinesia. Clin Neuropharmacol 2008;31:120-5. (Pubitemid 351489338)
42. Zesiewicz TA, Sullivan KL, Hauser RA. Levodopa-induced dyskinesia in Parkinson's disease: epidemiology, etiology, and treatment. CurrNeurol Neurosci Rep 2007;7:302-10. (Pubitemid 47103012)
43. Fahn S. How do you treat motor complications in Parkinson's disease: medicine, surgery, or both? Ann Neurol 2008;64:S56-64.
44. Muller T, Russ H, Hock K. Prevalence and treatment strategies of dyskinesia in patients with Parkinson's disease. J Neural Transm 2007;114:1023-6. (Pubitemid 47106454)
45. Van Gerpen JA, Kumar N, Bower JH, Weigand S, Ahlskog JE. Levodopa-associated dyskinesia risk among Parkinson disease patients in Olmstend Count, Minnesota, 1976-1990. Arch Neurol 2006;63:205-9. (Pubitemid 43261731)
46. Verhagen Metman L, Del Dotto P, van den Munckhof P, Fang J, Mouradian MM, Chase TN. Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease. Neurology 1998;50:1323-6. (Pubitemid 28240346)
47. Thanvi B, Lo N, Robinson T. Levodopa-induced dyskinesia in Parkinson's disease: clinical features, pathogenesis, prevention and treatment. Postgrad Med J 2007;83:384-8. (Pubitemid 46960824)
48. Charles DP, Padaliya BB, Newman WJ, Gill CE, Covington CD, Fang JY, et al. Deep brain stimulation of the subthalamic nucleus reduces antiparkinsonian medication costs. Parkinsonism Relat Disord 2004;10:475-9. (Pubitemid 39489880)
49. Kumar R, Lozano AM, Kim YJ, Hutchison WD, Sime E, Halket E, et al. Double-blind evaluation of subthalamic nucleus deep brain stimulation in advanced Parkinson's disease. Neurology 1998;51:850-5. (Pubitemid 28449271)
50. Limousin P, Krack P, Pollak P, Benazzouz A, Ardouin C, Hoffmann D, et al. Electrical stimulation of the subthalamic nucleus in advanced Parkinson's disease. N Engl J Med 1998;339:1105-11. (Pubitemid 28465758)
51. Brooks DJ, Sagar H. Entacapone is beneficial in both fluctuating and non-fluctuating patients with Parkinson's disease: a randomised, placebo controlled, double blind, six month study. J Neurol Neurosurg Psychiatry 2003;74:1071-9.